[go: up one dir, main page]

PE20071236A1 - Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina - Google Patents

Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina

Info

Publication number
PE20071236A1
PE20071236A1 PE2007000089A PE2007000089A PE20071236A1 PE 20071236 A1 PE20071236 A1 PE 20071236A1 PE 2007000089 A PE2007000089 A PE 2007000089A PE 2007000089 A PE2007000089 A PE 2007000089A PE 20071236 A1 PE20071236 A1 PE 20071236A1
Authority
PE
Peru
Prior art keywords
alkyl
modulators
oxobutan
piperidin
chlorophenyl
Prior art date
Application number
PE2007000089A
Other languages
English (en)
Inventor
Percy H Carter
Cullen L Cavallaro
John V Duncia
Daniel S Gardner
John Hynes
Rui-Qin Liu
Joseph B Santella
Dharmpal S Dodd
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20071236A1 publication Critical patent/PE20071236A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/38—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIPERIDINILO DE FORMULA (I), DONDE LA LINEA PUNTEADA REPRESENTA UN DOBLE ENLACE OPCIONAL; T ES -C(=O)-, -c(=O)-O-, -C(=O)-NR8- O -S(=O)2-; R1 ES ALQUILO, ARILO, HETEROARILO, ENTRE OTROS; R2 ES ALQUILO, CICLOALQUILO, ALQUENILO, ENTRE OTROS; R3 ES ALQUILO O JUNTO AL ATOMO DE CARBONO QUE ESTAN ENLAZADOS FORMAN UN ANILLO DE 3 A 6 MIEMBROS; W ES F, OH, CN, NH2; R5 ES HALO, CN O -O-ALQUILO; m ES UN ENTERO DE 0 A 2; n ES UN ENTERO DE 1 A 3. SON COMPUESTOS PREFERIDOS: (R)-N-(1-(4-(4-CLOROFENIL)PIPERIDIN-1-IL)-1-OXOBUTAN-2-IL)BENZAMIDA, (R)-N-(1-(4-(4-CLOROFENIL)PIPERIDIN-1-IL)-1-OXOBUTAN-2-IL)-4-METILPENTANAMIDA, (R)-N-(1-(4-(4-CLOROFENIL)PIPERIDIN-1-IL)-1-OXOBUTAN-2-IL)-3-METILBUTANAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE QUIMIOCINAS, PARTICULARMENTE MIP-1ALFA Y CCR-1, Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS TALES COMO EL ASMA Y ENFERMEDADES ALERGICA, PATOLOGIAS AUTOINMUNES, ENTRE OTRAS
PE2007000089A 2006-01-27 2007-01-25 Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina PE20071236A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76280106P 2006-01-27 2006-01-27
US11/625,874 US7601844B2 (en) 2006-01-27 2007-01-23 Piperidinyl derivatives as modulators of chemokine receptor activity

Publications (1)

Publication Number Publication Date
PE20071236A1 true PE20071236A1 (es) 2007-12-14

Family

ID=38335618

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000089A PE20071236A1 (es) 2006-01-27 2007-01-25 Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina

Country Status (16)

Country Link
US (3) US7601844B2 (es)
EP (3) EP2471774B1 (es)
JP (1) JP5124481B2 (es)
KR (1) KR101348491B1 (es)
AR (1) AR059229A1 (es)
AU (1) AU2007212236B2 (es)
BR (1) BRPI0707307A2 (es)
CA (1) CA2651987C (es)
EA (1) EA019192B1 (es)
IL (1) IL192976A (es)
MX (1) MX2008009512A (es)
NO (1) NO20083359L (es)
NZ (1) NZ570036A (es)
PE (1) PE20071236A1 (es)
TW (1) TWI424993B (es)
WO (1) WO2007092681A2 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
CA2666406A1 (en) * 2006-10-16 2008-04-24 Gruenenthal Gmbh Substituted sulfonamide derivatives for use as bradykinin 1 receptor modulators
WO2009015164A2 (en) * 2007-07-24 2009-01-29 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
JP5292400B2 (ja) * 2007-07-24 2013-09-18 ブリストル−マイヤーズ スクイブ カンパニー ケモカイン受容体活性のモジュレーターとしてのピペリジン誘導体
WO2009080227A2 (en) * 2007-12-26 2009-07-02 Sanofi-Aventis Pyrazole-carboxamide derivatives as p2y12 antagonists
ES2424661T3 (es) 2008-03-07 2013-10-07 Bristol-Myers Squibb Company Hidroxialcanil amidas como moduladores de la actividad del receptor de quimioquina
KR20100125316A (ko) * 2008-03-26 2010-11-30 다이이찌 산쿄 가부시키가이샤 하이드록시퀴녹살린카르복사마이드 유도체
EP2626361B1 (en) 2008-04-24 2014-10-15 F2G Limited Pyrrole antifungal agents
WO2009133834A1 (ja) * 2008-04-28 2009-11-05 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するケトアミド誘導体
US7829574B2 (en) * 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
TWI433838B (zh) * 2008-06-25 2014-04-11 必治妥美雅史谷比公司 作為趨化因子受體活性調節劑之六氫吡啶衍生物
WO2010087471A1 (ja) * 2009-02-02 2010-08-05 第一三共株式会社 ヒドロキシピラジンカルボキサミド誘導体
WO2010094242A1 (en) * 2009-02-20 2010-08-26 Merck Sharp & Dohme Corp. Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
GB0912975D0 (en) * 2009-07-24 2009-09-02 Syngenta Ltd Formulations
US8877749B2 (en) 2009-10-07 2014-11-04 Bristol-Myers Squibbs Company Spirocyclic compounds as modulators of chemokine receptor activity
US8410139B2 (en) * 2009-10-07 2013-04-02 Bristol-Myers Squibb Company Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity
AU2011224417B2 (en) * 2010-03-10 2015-02-19 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
US8686152B2 (en) 2010-03-10 2014-04-01 Janssen Pharmaceutica Nv 4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)
ES2553143T3 (es) * 2010-03-25 2015-12-04 Abbvie Inc. Agentes inductores de apoptosis para el tratamiento del cáncer y de enfermedades inmunitarias y autoinmunitarias
US8642622B2 (en) 2010-06-16 2014-02-04 Bristol-Myers Squibb Company Piperidinyl compound as a modulator of chemokine receptor activity
FR2962649A1 (fr) * 2010-07-19 2012-01-20 Conservatoire Nat Arts Et Metiers Traitement d'une pathologie liee a un effet excessif du tnf par un compose de benzene sulfonamide
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc HETEROCYCLIC TYROSINE KINASE HEMMER
EP2708537A4 (en) * 2011-05-10 2014-10-01 Taisho Pharmaceutical Co Ltd HETEROAROMATIC RING DERIVATIVE
CN103732589B (zh) 2011-05-25 2016-03-30 百时美施贵宝公司 可用作抗细胞凋亡bcl抑制剂的取代的磺酰胺
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
JP2015512891A (ja) 2012-03-13 2015-04-30 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ 殺菌性ピリミジン化合物
WO2013162984A1 (en) 2012-04-25 2013-10-31 Bristol-Myers Squibb Company Methods for identifying subjects with an increased likelihood of responding to ccr1 antagonist
FR3000065A1 (fr) * 2012-12-21 2014-06-27 Univ Lille Ii Droit & Sante Composes bicycliques ayant une activite potentialisatrice de l'activite d'un antibiotique actif contre les mycobacteries-composition et produit pharmaceutiques comprenant de tels composes
TWI752457B (zh) 2012-12-21 2022-01-11 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
CA2900309A1 (fr) * 2013-02-14 2014-08-21 Galderma Research & Development Procede de synthese de 4-piperidin-4-yl-benzene-1,3-diol et de ses sels et nouveau compose 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle
MX364743B (es) * 2013-07-11 2019-05-06 Evestra Inc Profármacos de formación de compuestos.
NO2865735T3 (es) 2013-07-12 2018-07-21
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CA2923101A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
MX2016013049A (es) 2014-04-04 2017-04-27 X-Rx Inc Inhibidores de autotaxina espirociclicos sustituidos.
WO2015175171A1 (en) * 2014-04-23 2015-11-19 X-Rx Discovery, Inc. Substituted n-(2-(amino)-2-oxoethyl)benzamide inhibitors of autotaxin and their preparation and use in the treatment of lpa-dependent or lpa-mediated diseases
NO2717902T3 (es) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI677489B (zh) 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
EP3221308B1 (en) 2014-11-21 2018-09-19 F2G Limited Antifungal agents
AU2016212053B2 (en) * 2015-01-30 2019-09-19 Basf Se Herbicidal phenylpyrimidines
RU2612970C1 (ru) * 2015-10-05 2017-03-14 Федеральное государственное казённое военное образовательное учреждение высшего профессионального образования "Военная академия радиационной, химической и биологической защиты имени Маршала Советского Союза С.К. Тимошенко" г. Кострома Министерства обороны Российской Федерации Способ получения 1-бензил-4-пропиоанилидо-4-пиперидинкарбонитрила
EP3512839A4 (en) * 2016-09-18 2020-03-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. YAP1 INHIBITORS TARGETING THE INTERACTION OF YAP1 WITH OCT4
NZ752196A (en) * 2016-09-21 2022-05-27 Vectus Biosystems Ltd Compositions for the treatment of hypertension and/or fibrosis
KR102635936B1 (ko) 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
CN110357833B (zh) * 2019-06-03 2022-05-24 杭州维坦医药科技有限公司 芳杂乙酰胺类衍生物及其制备和应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60163855A (ja) * 1984-02-06 1985-08-26 Mitsubishi Chem Ind Ltd アルギニン誘導体および薬剤として許容され得るその酸付加塩
GB9104656D0 (en) 1991-03-05 1991-04-17 Zambeletti Spa L Pharmaceuticals
DE4243858A1 (de) 1992-12-23 1994-06-30 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5459151A (en) 1993-04-30 1995-10-17 American Home Products Corporation N-acyl substituted phenyl piperidines as bronchodilators and antiinflammatory agents
US5492920A (en) * 1993-12-10 1996-02-20 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
US5777112A (en) 1994-06-13 1998-07-07 Merck & Co., Inc Piperazine compounds promote release of growth hormone
CN1195343A (zh) 1995-07-13 1998-10-07 千寿制药株式会社 哌啶衍生物及其用途
EP0944388A4 (en) 1996-04-03 2001-08-16 Merck & Co Inc INHIBITORS OF FARNESYL PROTEIN TRANSFERASE
ES2314305T3 (es) 1996-09-10 2009-03-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Aminoacidos modificados, medicamentos que contienen estos compuestos y procedimiento para su obtencion.
JP4024309B2 (ja) 1996-10-22 2007-12-19 第一三共株式会社 新規な感染症治療薬
US5847148A (en) 1997-04-10 1998-12-08 Pharmacia & Upjohn Company Thiadiazole derivatives useful for the treatment of diseases related to connective tissue degradation
ZA987383B (en) 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
EP1079825B1 (en) * 1998-04-16 2010-07-21 Encysive Pharmaceuticals, Inc Compounds that inhibit the binding of integrins to their receptors
NZ512282A (en) * 1998-12-17 2002-09-27 Wyeth Corp Arylpiperidine and aryl-1,2,5,6-tetrahydropyridine amide derivatives having 5HT1A receptor activity
US6391865B1 (en) 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
EP1187614A4 (en) 1999-06-04 2005-06-22 Merck & Co Inc SUBSTITUTED PIPERIDINES THAN MELANOCORTIN-4 RECEPTOR AGONISTS
DE10041402A1 (de) * 2000-08-23 2002-03-14 Morphochem Ag Neue Verbindungen, die Faktor Xa-Aktivität inhibieren
JP2001354657A (ja) 2000-06-09 2001-12-25 Sds Biotech:Kk 置換ピペラジン誘導体及び農園芸用殺菌剤
WO2001098268A2 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Piperidine amides as modulators of chemokine receptor activity
ES2246390T3 (es) 2001-01-23 2006-02-16 Eli Lilly And Company Derivados de piperazina como agonistas del receptor de melanocortina.
WO2002079146A2 (en) 2001-03-02 2002-10-10 Bristol-Myers Squibb Company Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
DE10124041A1 (de) 2001-05-16 2002-11-21 Graffinity Pharm Design Gmbh Protease Inhibitoren
DE60229393D1 (de) 2001-07-18 2008-11-27 Merck & Co Inc Überbrückte piperidinderivate als melanocortin-rezeptor-agonisten
US6977264B2 (en) 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
JP4320252B2 (ja) 2001-09-06 2009-08-26 シェーリング コーポレイション アンドロゲン依存性疾患の処置のための１β−ヒドロキシステロイドデヒドロゲナーゼ３型インヒビター
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
US20030229067A1 (en) 2001-12-20 2003-12-11 Arlindo Castelhano Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
GB0224917D0 (en) 2002-10-25 2002-12-04 Novartis Ag Organic compounds
US20050250814A1 (en) 2002-10-30 2005-11-10 Cangyou Zhou Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor
EP1599447A1 (en) 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
US6846836B2 (en) * 2003-04-18 2005-01-25 Bristol-Myers Squibb Company N-substituted phenylurea inhibitors of mitochondrial F1F0 ATP hydrolase
EP1633737A1 (en) 2003-06-13 2006-03-15 Schering Aktiengesellschaft Quinolyl amide derivatives as ccr-5 antagonists
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
DE10358539A1 (de) * 2003-12-15 2005-07-07 Merck Patent Gmbh Carbonsäureamidderivate
WO2005084672A1 (de) 2004-03-03 2005-09-15 Boehringer Ingelheim International Gmbh Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2005095327A1 (ja) * 2004-03-31 2005-10-13 Ajinomoto Co., Inc. アニリン誘導体
GB0412468D0 (en) 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US7723360B2 (en) 2004-08-06 2010-05-25 Boehringer Ingelheim International Gmbh Alkyl-and piperidine-substituted benzimidazole derivatives
US7576106B2 (en) * 2005-10-11 2009-08-18 Chemocentryx, Inc. Piperidine derivatives and methods of use
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US7615556B2 (en) * 2006-01-27 2009-11-10 Bristol-Myers Squibb Company Piperazinyl derivatives as modulators of chemokine receptor activity
WO2009015164A2 (en) * 2007-07-24 2009-01-29 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity

Also Published As

Publication number Publication date
US7601844B2 (en) 2009-10-13
WO2007092681A2 (en) 2007-08-16
JP2009526764A (ja) 2009-07-23
EP2471773A1 (en) 2012-07-04
EP2049486A2 (en) 2009-04-22
NZ570036A (en) 2011-06-30
TWI424993B (zh) 2014-02-01
AU2007212236A1 (en) 2007-08-16
BRPI0707307A2 (pt) 2011-05-03
CA2651987C (en) 2014-09-23
IL192976A (en) 2015-05-31
AR059229A1 (es) 2008-03-19
US7985861B2 (en) 2011-07-26
NO20083359L (no) 2008-10-15
EP2471774B1 (en) 2016-08-24
KR101348491B1 (ko) 2014-01-06
US20090298833A1 (en) 2009-12-03
TW200738660A (en) 2007-10-16
EP2471773B1 (en) 2016-03-23
US20110245226A1 (en) 2011-10-06
MX2008009512A (es) 2009-02-26
US20070208056A1 (en) 2007-09-06
WO2007092681A3 (en) 2009-03-12
CA2651987A1 (en) 2007-08-16
EA019192B1 (ru) 2014-01-30
JP5124481B2 (ja) 2013-01-23
KR20080095890A (ko) 2008-10-29
EA200801757A1 (ru) 2009-08-28
AU2007212236B2 (en) 2012-05-24
EP2471774A1 (en) 2012-07-04

Similar Documents

Publication Publication Date Title
PE20071236A1 (es) Derivados de piperidinilo como moduladores de la actividad del receptor de quimiocina
PE20081838A1 (es) Derivados de ester o amida de imidazolilo como moduladores del receptor glucocorticoide
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
PE20081385A1 (es) Derivados de nicotinamida
PE20091974A1 (es) Derivados de indazoles sustituidos con fenil o piridinilo
PE20081227A1 (es) Derivados indazolil sulfonamidas como moduladores de glucocorticoides
MX2009004441A (es) Derivados de indazol utiles como inhibidores de las isoformas de higado.
NO20082346L (no) Hydrazonderivater og anvendelser derav
TW200745032A (en) Novel heterobicyclic derivatives
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
PE20061366A1 (es) Compuestos y composiciones como inhibidores de quinasa de proteina
CO5700757A2 (es) Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
TW200738655A (en) Novel bicyclic sulfonamide derivatives
AR068055A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
CL2008003384A1 (es) Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
PE20070138A1 (es) Compuestos heterociclicos como inhibidores de aspartil proteasas
ECSP066958A (es) Compuestos de morfolina
AR060536A1 (es) Agonista del receptor de glucocorticoides y composiciones farmaceuticas
PE20110398A1 (es) BENZAMIDAS CON ACTIVIDAD SOBRE LA ENZIMA p38 MAP-QUINASA
PE20150194A1 (es) Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
PE20141352A1 (es) Fenil-3-aza-biciclo[3,1,0]hex-3-il-metanonas y su uso como medicamento
ECSP088731A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparación y las composiciones farmacéuticas que las contienen

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed